Dr. Jacqueline Lui, President of Eagle IP Group, gave a talk titled “進軍國際市場的知識產權策略” to the Hunan IP official delegates include Hunan government IP officials and leaders of IP trading and service industry.
我们的过去活动
Recommended Insights
China Patent Office (CNIPA) Releases More Details About Patent Term Adjustment (PTA) in the Draft Examination Guidelines
2021年10月19日The new 4th Amendment of the Chinese Patent Law came into effect on June 1, 2021. Right before that date, the Chinese Patent Office (“CNIPA”) released some “Interim Measures” to give us a taste of what was to come, though they have yet to released the actual Implementation Rules. Two months later, CNIPA finally released […]
阅读更多 >
What is the difference between an Invention Patent and a Utility Model Patent?
2021年8月13日There are two types of patent protection in China. Invention patents (similar to a US utility patent) have a term of 20 years from the date of filing and may be granted for both methods and products. Utility model patents (similar to a petty patent) may be granted in China for technical solutions that relate […]
阅读更多 >
No % homology? How to craft allowable claim scope around sequences to comply with China’s strict written description requirements
2018年11月23日Since 2010, the Patent Re-examination Board (PRB) has published the top 10 patent invalidation cases of the year in April of each year. The selection criteria are high social concern, significant impact on the related industry, or involve difficult legal issues and important examination criteria. Below is one of the top 10 cases that discusses […]
阅读更多 >
RNAi Patent Success in China: Overcoming “Comprising” Claim Challenges
2025年3月10日An Update on Sufficiency and Inventiveness of RNAi Patents in China RNAi is a fast-developing technology that has gained traction in the pharmaceutical industry as a promising therapeutic agent. It is important to follow closely RNAi patent proceedings to learn how different examination boards and courts understand and handle these new technologies. The first-ever invalidation […]
阅读更多 >